Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Switzerland-based Covis Pharma has signed an agreement to acquire commercial rights for Nilandron (nilutamide), Plaquenil (hydroxychloroquine), Rilutek (riluzole), Uroxatral (alfuzosin hydrochloride), and Kayexalate (sodium polystyrene sulfate) in the US from Sanofi-Aventis and its affiliates.
Subscribe to our email newsletter
The company’s US-based distributor Covis Pharmaceuticals will promote the products, manufactured and supplied by Sanofi, in the US.
Sanofi retains the rights for the products outside US.
Covis Pharma CEO Jack Davis said, "Covis will continue to supply consistent, top quality, branded pharmaceuticals, ensuring that patients receive the therapeutic care they need."
Terms of the agreement that obtained Hart-Scott-Rodino regulatory clearance in the US, were not revealed.